In this edition

3 signals for your next decision

  1. NewFinal classification order codifying a 2023 classification

    Home-collected diagnostics: validate the complete testing workflow

    What changed
    FDA codified Class II controls for home-collected, laboratory-tested STI nucleic-acid systems, covering prospective specimens, comparators, statistical planning, sample shipping, usability and result interpretation.
    Why it matters
    Japanese diagnostic teams need evidence across the patient-to-laboratory journey, including whether lay users collect specimens correctly.
    Consider next
    Define users, specimen types, shipping conditions, comparator and usability evidence before selecting collection kits or study sites.
    Sources & context1 source
    Relevant to
    Home-collected molecular diagnostics and laboratory tests paired with consumer collection kits
    Limits to keep in mind
    Published and effective October 9, 2026, this codifies a November 15, 2023 classification. It is not a new clearance or a blanket rule for all home diagnostics; the covered device type remains subject to 510(k).
    Source date: Oct 9, 2026Event / deadline: Oct 9, 2026
    FDA / Federal RegisterHome-collected STI nucleic-acid system classification
  2. NewFinal classification order codifying a 2023 classification

    Hereditary-cancer sequencing: map gene and variant evidence gaps

    What changed
    FDA codified Class II controls for hereditary-cancer predisposition sequencing, covering specimen handling, software validation, variant interpretation and accuracy against an appropriate orthogonal method.
    Why it matters
    Japanese genomic-diagnostic teams can assess whether existing datasets cover clinically important genes, difficult variants and predefined statistical criteria.
    Consider next
    Map gene and variant coverage, comparator methods and confidence intervals to the controls before commissioning additional U.S. testing.
    Sources & context1 source
    Relevant to
    Prescription germline cancer-predisposition NGS panels and interpretation software
    Limits to keep in mind
    The October 6, 2026 order codifies a September 29, 2023 classification. The covered device is not intended for screening, prenatal testing or stand-alone diagnosis; these controls do not establish a pathway for every cancer test.
    Source date: Oct 6, 2026Event / deadline: Oct 6, 2026
    FDA / Federal RegisterHereditary-cancer DNA sequencing system classification
  3. OngoingFDA paper synthesizing existing guidance

    Digital endpoints: connect technical performance to patient relevance

    What changed
    FDA’s August paper distinguishes technical verification, analytical validation and clinical validation for digitally derived clinical-investigation outcomes, emphasizing patient relevance, usability and error sources.
    Why it matters
    Japanese wearable and AI teams need to justify what a proposed endpoint measures in the intended population.
    Consider next
    Document context of use, the meaningful health concept and validation evidence; seek appropriate regulatory feedback before relying on a novel endpoint.
    Sources & context2 sources
    Relevant to
    Wearables, remote monitoring, digital biomarkers and AI-derived trial endpoints
    Limits to keep in mind
    Announced August 20, 2026, this paper draws on existing guidance. It is not new marketing authorization, mandatory standalone guidance or automatic acceptance of a digital endpoint.
    Source date: Aug 20, 2026Event / deadline: Aug 20, 2026
    FDADigitally derived measures paper overview
    FDADigitally derived measures paper